Iron Lactate Trihydrate

Iron lactate trihydrate is a ferrous iron salt (Fe²⁺ bound to lactate with three water molecules) used as a bioavailable source of elemental iron for correcting iron deficiency and supporting hemoglobin synthesis. The ferrous (Fe²⁺) oxidation state allows direct intestinal absorption via divalent metal transporter-1 (DMT-1) without requiring prior reduction, distinguishing it from ferric iron forms.

Category: Mineral Evidence: 2/10 Tier: Emerging
Iron Lactate Trihydrate — Hermetica Encyclopedia

Origin & History

Iron lactate trihydrate is a synthetic greenish-white powder with the formula C₆H₁₀FeO₆·3H₂O, consisting of iron(II) complexed with lactate ligands. It is produced chemically by reacting calcium lactate with iron(II) sulfate or combining lactic acid, calcium carbonate, and iron(II) sulfate, and has no biological origin.

Historical & Cultural Context

No historical or traditional medicinal uses are documented in the research. Iron lactate trihydrate is described solely as a modern synthetic food additive and supplement with no traditional use in systems like Ayurveda or TCM.

Health Benefits

• Iron supplementation for anemia - provides bioavailable ferrous iron (Fe²⁺) for hemoglobin production (evidence quality: general use noted, no specific trials)
• Support for erythropoiesis - ferrous iron utilized in red blood cell production pathways (evidence quality: biochemical mechanism described, no clinical data)
• Food fortificant approved as E585 - used in infant formulas and foods for iron fortification (evidence quality: regulatory approval noted)
• Heme synthesis support - provides key component for hemoglobin formation (evidence quality: theoretical based on iron biochemistry)
• Note: No specific clinical trials were found in the research dossier

How It Works

Iron lactate trihydrate dissociates in the acidic gastric environment to release ferrous iron (Fe²⁺), which is absorbed in the duodenum and proximal jejunum via divalent metal transporter-1 (DMT-1, encoded by SLC11A2). Once intracellular, ferrous iron is transferred to ferritin for storage or bound to transferrin in plasma for transport to erythroid precursor cells, where it is incorporated into protoporphyrin IX by ferrochelatase to form heme — the oxygen-carrying component of hemoglobin. The lactate anion may confer mild solubility advantages in near-neutral intestinal pH compared to some inorganic iron salts, potentially supporting absorption consistency.

Scientific Research

The research dossier provides no specific human clinical trials, RCTs, or meta-analyses for iron lactate trihydrate. No PubMed PMIDs are available in the sources, with only general uses as an iron fortificant for anemia noted without study details on design, sample size, or outcomes.

Clinical Summary

Iron lactate trihydrate lacks dedicated large-scale randomized controlled trials as a standalone intervention; available evidence is extrapolated from broader ferrous iron salt research and in vitro bioavailability comparisons. Studies on ferrous salts generally (including ferrous sulfate and ferrous gluconate) in iron-deficiency anemia populations demonstrate hemoglobin increases of approximately 1–2 g/dL over 4–12 weeks with standard elemental iron doses of 100–200 mg/day. A small number of comparative bioavailability studies in animal models suggest iron lactate has absorption profiles comparable to ferrous sulfate, though human pharmacokinetic trials are limited in number and sample size. Clinicians currently treat iron lactate trihydrate as a functionally equivalent ferrous iron source, with evidence strength rated as moderate for the iron class overall but low specifically for this salt form.

Nutritional Profile

Iron Lactate Trihydrate [Fe(C₃H₅O₃)₂·3H₂O] is a ferrous iron (Fe²⁺) salt of lactic acid with a molecular weight of approximately 288.0 g/mol. Iron content is approximately 19.4% by weight (roughly 194 mg elemental iron per gram of compound). As a ferrous (Fe²⁺) salt, it offers superior bioavailability compared to ferric (Fe³⁺) iron forms, as Fe²⁺ is directly absorbed via the DMT1 (divalent metal transporter 1) pathway in the duodenum and proximal jejunum. Absorption rate is estimated at 10–30% depending on individual iron status, with iron-deficient individuals absorbing at the higher end. The lactate anion (two moles per mole of iron) contributes negligible caloric value (~6.6 kcal/g lactate, but quantities used are minimal). Contains no protein, fat, fiber, vitamins, or other micronutrients. The trihydrate form contains approximately 18.8% water of crystallization by weight. Solubility in water is moderate (~5–7 g/100 mL at 20°C), which supports its use in liquid formulations and food fortification (E585). Bioavailability is enhanced when consumed with ascorbic acid (vitamin C), which maintains iron in the ferrous state and forms soluble iron-ascorbate chelates; conversely, bioavailability is reduced by phytates, polyphenols (tannins), calcium, and concurrent antacid use. Compared to ferrous sulfate (the clinical gold standard for oral iron), ferrous lactate may produce fewer gastrointestinal side effects due to the buffering properties of the lactate anion, though direct comparative bioavailability data are limited. The compound provides no significant amounts of macronutrients and is used strictly as an iron source. Typical supplemental doses deliver 15–65 mg elemental iron per serving depending on the formulation and indication.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are provided in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Vitamin B12, Folic acid, Copper, Vitamin B6

Safety & Interactions

Common side effects mirror those of other oral ferrous iron salts and include constipation, nausea, abdominal cramping, dark stools, and gastric irritation, particularly at elemental iron doses above 60 mg per dose. Iron supplementation is contraindicated in hemochromatosis, hemosiderosis, hemolytic anemias not associated with iron deficiency, and should be used cautiously in individuals with inflammatory bowel disease. Significant drug interactions include reduced absorption of fluoroquinolone and tetracycline antibiotics, levothyroxine, and bisphosphonates when co-administered — a minimum 2-hour separation is recommended. Iron supplementation is generally considered safe in pregnancy at prescribed doses (typically 27–45 mg elemental iron/day), as iron requirements increase substantially during gestation, though excess intake carries oxidative stress risks.